Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
Author(s) -
Alexandra Schäfer,
David R. Martinez,
John J. Won,
Rita M. Meganck,
Fernando R. Moreira,
Ariane J. Brown,
Kendra L. Gully,
Mark R. Zweigart,
William S. Conrad,
Samantha R. May,
Stephanie Dong,
Rao Kalla,
Kwon Soo Chun,
Venice Du Pont,
Darius Babusis,
Jennifer H. Tang,
Eisuke Murakami,
Raju Subramanian,
Kimberly T. Barrett,
Blake J. Bleier,
Roy Bannister,
Joy Y. Feng,
John P. Bilello,
Tomáš Cihlář,
Richard L. Mackman,
Stephanie A. Montgomery,
Ralph S. Baric,
Timothy P. Sheahan
Publication year - 2022
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/4t8n-4568
Subject(s) - prodrug , pathogenesis , covid-19 , medicine , virology , pharmacology , nucleoside , immunology , biology , genetics , infectious disease (medical specialty) , disease , outbreak
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom